Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 4 | Journal of Neuroinflammation

Fig. 4

From: Virus-mediated EpoR76E gene therapy preserves vision in a glaucoma model by modulating neuroinflammation and decreasing oxidative stress

Fig. 4

Treatment with rAAV.EpoR76E causes a decrease in pro-inflammatory cytokines and chemokines. a Bar graph of the percent decrease in pro-inflammatory cytokines in retinas from 8-month-old rAAV.EpoR76E-treated mice as compared to mice treated with rAAV.eGFP, *p < 0.05. b, c TNFα mRNA levels are increased in glaucoma and unaffected by treatment with rAAV.EpoR76E. Box and whisker plots of the delta Ct (b) and fold change (c) in TNFα mRNA in 3-month-old and 8-month-old mice treated with rAAV.EpoR76E or rAAV.eGFP, *p < 0.05

Back to article page